RecruitingRecruiting
A Non-interventional, Prospective Study With Benralizumab
NCT06422078 · AstraZeneca
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life
About this study
This is a prospective observational study to investigate the asthma control and health realted quality of life (HRQL) of benralizumab treated patients in routine clinical practice, their asthma medication intake, and their changes in asthma medication during the study, up to 52 weeks.
The asthma control will be analyzed by using the Asthma Control Test (ACT) and the Asthma Impairment and Risk Questionnaire (AIRQ®) at different timepoints during the study period either collected by the investigator or self-reported by the patient. In addition, health realted quality of life will be assessed at baseline and routine follow-up visits using the mini Asthma Quality of Life Questionnaire (miniAQLQ) which is collected by the investigator. To investigate the medication intake and assess the changes in asthma medication, the patients will record their weekly medication intake in a paper-based or an electronic medication diary throughout the study.
Eligibility criteria
Inclusion Criteria:
* Male or female patients aged 18 years or older
* Confirmed diagnosis of severe eosinophilic asthma (defined according to the European Respiratory Society and American Thoracic Society and local German guidelines) treated with high-dose inhaled corticosteroids (ICS) plus long-acting beta agonists (LABA)
* Prescribed treatment with benralizumab according to label and local market reimbursement criteria
* Benralizumab treatment was not part of the study decision and treatment decision was met prior and independently of the study
* Patients must be able and willing to read and comprehend written instructions
* After full explanation, patients must have signed an informed consent form (ICF) indicating that they understand the purpose of, and the procedures required for the study and are willing to participate in the study
* Patients must be willing to report asthma patient-reported outcomes (PROs) every 4 weeks and medication intake weekly
Exclusion Criteria:
* Patients who participate in an observational trial that might, in the investigators' opinion, influence the assessment for current study; or participated in a randomized clinical trial in the last 3 months
* History of anaphylaxis to any biologic therapy
* Prior treatment with any asthma biologic therapy within the last 3 months
* Concurrent asthma biologic therapy
* Helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent was obtained that had not been treated with, or had failed to respond to standard of care (SOC) therapy
* Any other pulmonary disease than asthma that, in the investigator's point of view, would have an impact on the interpretation of results
* An acute or chronic condition that, in the investigator's point of view, would limit the patient's ability to complete questionnaires or participate in this study or impact the interpretations of results
* Current or history of malignancy within 5 years before the enrolment date with the following exceptions:
* In-situ carcinoma of the cervix where curative therapy has been completed and patients are in remission for at least 12 months prior to enrolment date
* Basal cell or superficial squamous skin cancer
* Pregnancy or lactation period (status to be proactively asked by the investigator)
* Any condition, that, in the opinion of the investigator, could jeopardize the safety of the patient
Study design
Enrollment target: 300 participants
Age groups: adult, older_adult
Timeline
Starts: 2024-07-25
Estimated completion: 2027-12-31
Last updated: 2026-08-28
Primary outcomes
- • Change in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose (From baseline to week 12, 24 and 52)
- • Proportion of responders at baseline, week 12, 24 and 52 after first benralizumab dose, using ACT (At baseline, week 12, 24 and 52)
- • Change in daily doses of prescribed inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose (From baseline to week 12, 24 and 52)
Sponsor
AstraZeneca · industry
Contacts & investigators
ContactAstraZeneca Clinical Study Information Center · contact · information.center@astrazeneca.com · 1-877-240-9479
All locations (41)
Research SiteRecruiting
Ahrensburg, Germany
Research SiteRecruiting
Ansbach, Germany
Research SiteRecruiting
Aschaffenburg, Germany
Research SiteRecruiting
Auerbach, Germany
Research SiteRecruiting
Augsburg, Germany
Research SiteRecruiting
Bad Homburg, Germany
Research SiteRecruiting
Berlin, Germany
Research SiteRecruiting
Cottbus, Germany
Research SiteRecruiting
Darmstadt, Germany
Research SiteRecruiting
Dresden, Germany
Research SiteRecruiting
Düsseldorf, Germany
Research SiteRecruiting
Ehringshausen, Germany
Research SiteRecruiting
Erkelenz, Germany
Research SiteRecruiting
Essen, Germany
Research SiteRecruiting
Flensburg, Germany
Research SiteRecruiting
Frankfurt am Main, Germany
Research SiteRecruiting
Garmisch-Partenkirchen, Germany
Research SiteRecruiting
Halle, Germany
Research SiteRecruiting
Hamburg, Germany
Research SiteRecruiting
Hanover, Germany
Research SiteWithdrawn
Heidelberg, Germany
Research SiteRecruiting
Heidelberg, Germany
Research SiteRecruiting
Hohenstein-Ernsttahl, Germany
Research SiteRecruiting
Itzehoe, Germany
Research SiteRecruiting
Jena, Germany
Research SiteRecruiting
Leipzig, Germany
Research SiteRecruiting
Loerrach, Germany
Research SiteRecruiting
Lübeck, Germany
Research SiteRecruiting
Lüneburg, Germany
Research SiteRecruiting
Markkleeberg, Germany
Research SiteRecruiting
Mönchengladbach, Germany
Research SiteRecruiting
Neuruppin, Germany
Research SiteRecruiting
Nuremberg, Germany
Research SiteRecruiting
Papenburg, Germany
Research SiteRecruiting
Rostock, Germany
Research SiteRecruiting
Saalfeld, Germany
Research SiteRecruiting
Spardorf, Germany
Research SiteRecruiting
Weißenburg, Germany
Research SiteRecruiting
Wilhelmshaven, Germany
Research SiteRecruiting
Würzburg, Germany
Research SiteRecruiting
Zossen, Germany